Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1729651

CC1CCCN1C1CCN(c2ccc(NC(=O)NCc3cccs3)cc2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 17/20 0.89
CYP3A4 P08684 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
KCNH2 Q12809 2/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728440 0.94 HRH3 (1.00) HRH3CYP3A4KDM4EALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL1729811 0.88 HRH3 (0.90) HRH3CYP3A4KDM4EALDH1A1KCNH2
Trifluoroacetic Acid SCHEMBL2421036 0.84 HRH3 (0.62) HRH3ALDH1A1MAPTMAPK1KCNH2
SCHEMBL1728412 0.82 HRH3 (1.00) HRH3CYP3A4KDM4EALDH1A1NPC1
Trifluoroacetic Acid SCHEMBL2994664 0.80 HRH3 (0.87) HRH3CYP3A4KCNH2
Trifluoroacetic Acid SCHEMBL223740 0.79 HRH3 (0.65) HRH3CYP3A4KCNH2
Trifluoroacetic Acid SCHEMBL1727989 0.79 HRH3 (0.87) HRH3CYP3A4KCNH2
Trifluoroacetic Acid SCHEMBL222758 0.79 HRH3 (0.62) HRH3CYP3A4KCNH2
Trifluoroacetic Acid SCHEMBL1728317 0.78 HRH3 (0.86) HRH3CYP3A4KCNH2
Trifluoroacetic Acid SCHEMBL222651 0.78 HRH3 (0.67) HRH3CYP3A4ALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222290-B2 Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof SANOFI (FR) 2012-07-17 US disclosed
EP-2215058-B1 SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2011-11-23 EP disclosed
US-20100173908-A1 SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173908-A1 SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF HRH3, HRH4, UTS2R HRH3 1/4885CYP3A4 737/4885KDM4E 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.